MedinCell SA

As of March 31, 2026, MedinCell SA carries a market capitalization of 815.08M, placing it among publicly traded companies globally. Its enterprise value stands at 787.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MedinCell SA's next confirmed earnings release is scheduled for December 9, 2026.

As of March 31, 2026, MedinCell SA has 35.91M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, MedinCell SA maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, MedinCell SA's stock has declined approximately 21.80% over the past 52 weeks. The 50-day moving average sits at 23.58, while the 200-day moving average is 24.73.

As of March 31, 2026, MedinCell SA holds 84.82M in cash and equivalents against 57.41M in total debt, resulting in a net debt position of -7.77M. Total book value stands at 3.06M, with working capital of 76.02M providing operational flexibility.